Healthcare
Live Price
Offline$0.801
-6.75% today
1Y Change
-53.70%
Window
Jun 23, 2025 → Jun 18, 2026
Coverage: 249 bars · Jun 23, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
TELA Bio, Inc. (TELA) is a Healthcare stock with a market cap of $40.00M and listed on NASDAQ. The stock last traded around $0.80 and down 53.7% across the available one-year price window (Jun 23, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of +15.8%, EPS growth of +37.6%, a dividend yield of 0.0%. What stands out right now is revenue +15.8%, EPS +37.6%, free cash flow +32.7% with operating margin -42.0% and ROIC -53.2%. Valuation is more restrained than many high-expectation growth names at price/sales 0.6. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines TELA price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TELA
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
TELA Max Drawdown
-73.83%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for TELA and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$29.5M
-28.9% YoY
FY Net Income
-$33.3M
+24.9% YoY
Free Cash Flow
-$31.1M
+27.1% YoY
Revenue Growth
+15.8%
EPS Growth
+37.6%
Gross Margin
67.7%
Net Margin
-48.4%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 80M | 69M | 58M | 41M | 29M |
| Gross Profit | 54M | 46M | 40M | 27M | 19M |
| Operating Income | -34M | -34M | -44M | -39M | -29M |
| EBITDA | -34M | -32M | -41M | -39M | -29M |
| Net Income | -39M | -38M | -47M | -44M | -33M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 51M | 53M | 47M | 42M | 44M |
| Total Assets | 81M | 87M | 78M | 68M | 63M |
| Total Liabilities | 75M | 59M | 59M | 54M | 42M |
| Shareholder Equity | 6M | 28M | 19M | 14M | 20M |
| Total Debt | 56M | 43M | 43M | 41M | 31M |
| Net Debt | 5M | -10M | -4M | -563K | -12M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
30M
+25.3% YoY
Capital Expenditures
627K
+66.5% YoY
Free Cash Flow
31M
+27.1% YoY
Key ratios
Gross Margin
67.7%
Operating Margin
-42.0%
Net Margin
-48.4%
ROE
-441.5%
Debt / Equity
8.82x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.